Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC decreased its position in Evolus, Inc. (NASDAQ:EOLS) by 58.8% during the 2nd quarter, Holdings Channel reports. The fund owned 2,954 shares of the company’s stock after selling 4,208 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Evolus were worth $32,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Perceptive Advisors LLC grew its holdings in shares of Evolus by 166.8% during the fourth quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock worth $41,735,000 after purchasing an additional 2,477,623 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in Evolus by 5,627.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock worth $10,276,000 after buying an additional 930,566 shares during the last quarter. Lord Abbett & CO. LLC acquired a new position in Evolus during the first quarter worth approximately $11,628,000. Zimmer Partners LP purchased a new stake in Evolus in the first quarter valued at approximately $4,200,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Evolus by 84.2% in the first quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock valued at $5,683,000 after acquiring an additional 185,532 shares during the period. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Insiders Place Their Bets

In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the transaction, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the transaction, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at $1,305,643.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the sale, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. The disclosure for this sale can be found here. 6.10% of the stock is owned by corporate insiders.

Evolus Trading Up 2.6 %

NASDAQ:EOLS opened at $15.09 on Tuesday. Evolus, Inc. has a 52-week low of $7.44 and a 52-week high of $16.29. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 6.26. The stock has a fifty day simple moving average of $13.34 and a 200-day simple moving average of $12.99. The company has a market capitalization of $952.03 million, a PE ratio of -14.37 and a beta of 1.30.

Evolus (NASDAQ:EOLS) last announced its earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The business had revenue of $66.91 million for the quarter, compared to the consensus estimate of $65.06 million. On average, equities research analysts expect that Evolus, Inc. will post -0.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a report on Thursday, August 1st. HC Wainwright restated a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research note on Thursday, August 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a research note on Monday.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.